Skip to main
HOLX

Hologic (HOLX) Stock Forecast & Price Target

Hologic (HOLX) Analyst Ratings

Based on 12 analyst ratings
Hold
Strong Buy 17%
Buy 17%
Hold 67%
Sell 0%
Strong Sell 0%

Bulls say

Hologic is positioned for positive growth due to anticipated organic revenue growth of 5-7%, driven by strong procedure volume increases, new product launches, and strategic tuck-in acquisitions across its Diagnostics, Breast Health, and GYN Surgical segments. The company’s bull case scenario projects revenue growth potentially accelerating to the high single digits (7-9%), supported by improvements in operating margins and a robust balance sheet with limited leverage. Additionally, expected operational efficiencies could deliver 8-12% earnings growth, further enhancing the overall financial outlook as business trends exhibit increasing favorability.

Bears say

Hologic faces a negative outlook primarily due to projected revenue growth slowing to low-single digits, attributed to weaknesses in both the Diagnostics and Breast Health segments, which are critical to its business model. The company has experienced disappointing returns over the past three and five years, with recent trends suggesting that anticipated growth in revenue and operational margins may not materialize, particularly amidst sluggish demand in Breast Health. Additional risks include potential market share loss, challenges related to integration from recent acquisitions, and a broader economic downturn that could further depress demand across its product offerings.

Hologic (HOLX) has been analyzed by 12 analysts, with a consensus rating of Hold. 17% of analysts recommend a Strong Buy, 17% recommend Buy, 67% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Hologic and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Hologic (HOLX) Forecast

Analysts have given Hologic (HOLX) a Hold based on their latest research and market trends.

According to 12 analysts, Hologic (HOLX) has a Hold consensus rating as of Jan 8, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $79.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $79.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Hologic (HOLX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.